LiveCareer
LiveCareer
  • Dashboard
  • Jobs
  • Resumes
  • Cover Letters
  • Resumes
    • Resumes
    • Resume Builder
    • Resume Examples
      • Resume Examples
      • Nursing
      • Education
      • Administrative
      • Medical
      • Human Resources
      • View All
    • Resume Search
    • Resume Templates
      • Resume Templates
      • Nursing
      • Education
      • Medical
      • Human Resources
      • Customer Service
      • View All
    • Resume Services
    • Resume Formats
    • Resume Review
    • How to Write a Resume
    • CV Examples
    • CV Formats
    • CV Templates
    • Resume Objectives
  • Cover Letters
    • Cover Letters
    • Cover Letter Builder
    • Cover Letter Examples
      • Cover Letter Examples
      • Education
      • Medical
      • Human Resources
      • Customer Service
      • Business Operations
      • View All
    • Cover Letter Services
    • Cover Letter Templates
    • Cover Letter Formats
    • How to Write a Cover Letter
  • Jobs
    • Mobile App
    • Job Search
    • Job Apply Tool
    • Salary Calculator
    • Business Letters
    • Job Descriptions
  • Questions
  • Resources
  • About
  • Contact
  • 0Notifications
    • Notifications

      0 New
  • jane
    • Settings
    • Help & Support
    • Sign Out
  • Sign In
Member Login
  • LiveCareer
  • Resume Search
  • Senior Scientist
Please provide a type of job or location to search!
SEARCH

Senior Scientist Resume Example

Resume Score: 80%

Love this resume?Build Your Own Now
SENIOR SCIENTIST
Summary

Versatile Senior Scientist bringing advanced understanding of drug discovery developed over 11-year career and proven track record of successful development of cell-based analytical assay for drug development process including 6 years in microRNA gene therapy and 4 years in biologics. Excellent critical thinking, complex problem-solving and decision-making abilities with good grasp of business requirements and industry trends. Ready to apply knowledge and abilities to growth-oriented position with Neurocrine Biosciences.

Skills
  • Broad literature knowledge of a variety of target classes (enzymes, proteins, microRNA) and the ability to distill critical functional parameters from literature and adapt them into functional assay concepts.
  • Demonstrated expertise in mammalian cell culture of different scales, cell-based analytical assay development and validation for drug development process
  • Good understanding of AAV based gene therapy products, cGMP and ICH guideline
  • Collaboration; Project management; Time and resource evaluation and management; Data collection, management and analysis
Experience
Senior Scientist, Metacrine Inc., August 2017-February 2020San Diego, CA
  • Supported project leads in preparing regulatory documentation and presentations highlighting findings.
  • Served as lead scientist to define scientific approach, develop and execute cell-based assays to support company portfolio drug discovery and development programs for both large molecule biologics and small molecule inhibitors
  • Routinely-executed analytical assays in the context of biological potency include but not limited to ELISA, enzymatic assays, mRNA knockdown
  • Managed numerous projects simultaneously within budgetary restrictions.
Scientist-Senior Scientist, Regulus Therapeutics, August 2011-May 2017San Diego, CA
  • Built and led a team to investigate function of microRNA antagonism using both cell-based assays and experimental animal models
  • Utilized cGMP grade AAV-packaged microRNA inhibitor to interrogate microRNA function in vitro and in vivo
  • Routinely-executed analytical assay format included but not limited to ELISA, MSD, flow cytometry, RT-qPCR
  • Develop and deliver scientific presentations, prepare clear and concise technical reports, participate or lead project teams
  • Experienced with cGMP compliance requirements, ICH guidelines for analytical testing, and excellent organizational skills
  • Demonstrated ability to work in a matrixed environment and interact productively with associates, scientists, and management at various levels
Postdoctoral Fellow, Johnson And Johnson, Immunology Department, August 2009-August 2011La Jolla, CA
  • Designed and executed primary immune cell-based analytical assays to evaluate GPCR-mediated function by flow cytometry analysis
  • Demonstrated scientific excellency by contributing to high impact journal publication by generating high-quality data to test scientific hypothesis
  • Collaborated closely with multi-disciplinary teams and delivered critical results in a timely fashion and awarded with JNJ Outstanding Leadership Award
Postdoctoral Research Associate, The Scripps Research Institute, August 2004-August 2009La Jolla, CA
  • Designed and executed numerous cell based analytical assays to examine engineered protein variant function.
  • Implemented recombinant protein variant generation and production process using HEK293 cell factory
  • Helped write and review manuscripts for publication in scientific journals.
Education and Training
Ph.D.Biochemistry, , , Temple University, , PhiladelphiaPAJuly 2004
Bachelor of ScienceBiological Science, , Wuhan University, , Wuhan, ChinaJuly 1999
Fun Activities

Reading, Journaling, Volunteer, Golf, Yoga, Marathon, Tennis, Travel

Publications

PAPERS:
1. Huang X, Magnus J, Kaimal V, Karmali P, Li J, Walls M, Prudente R, Sung E, Sorourian M, Lee R, Davis S, Yang X, Estrella H, Lee EC, Chau BN, Pavlicek A, Zabludoff S. Lipid Nanoparticle-Mediated
Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth, Mol Cancer Ther. 2017 May;16(5):905-913
2. Sinha RK, Yang X, Fernández JA, Xu X, Mosnier LO, Griffin JH Apolipoprotein E Receptor 2 Mediates Activated Protein C–Induced Endothelial Akt Activation and Endothelial Barrier Stabilization, ATVB, 2016;36:518-524
3. Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, Yu J, Nelen MI, Liu X, Castro G, Luna R, Crawford S, Banie H, Dandridge RA, Deng X, Bittner A, Kuei C, Tootoonchi M, Rozenkrants N, Herman K, Gao J, Yang X, Sachen K, Ngo K, Fung-Leung WP, Nguyen S, de Leon-Tabaldo A, Blevitt J, Zhang Y, Cummings MD, Rao T, Mani NS, Liu C, McKinnon M, Milla ME, Fourie AM, Sun S.
Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Proc Natl Acad Sci U S
A. 2014 Aug 19;111(33):12163-8
4. Zhang L, Shih AY, Yang X, Kuei C, Wu J, Deng X, Mani NS, Mirzadegan T, Sun S, Lovenberg TW, Liu C. Identification of structural motifs critical for epstein-barr virusinduced molecule function and homology modeling of the ligand docking site. Mol Pharmacol. 2012 Dec;82(6):1094-103
5. Liu CL, Yang X, Wu JJ, Kuei C, Mani NS, Zhang L, Yu JX, Sutton SW, Qin N, Banie H, Karlsson L, Sun SQ, Lovenberg TW. Oxysterols direct B-cell migration through EBI2, Nature. Jul 27;475(7357):519-23
6. Yang X, Banerjee Y, Fernández JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, WhiteAdams TC, McCarty OJ, Griffin JH. Activated protein C ligation of ApoER2 (LRP8) causes Dab1dependent signaling in U937 cells. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):274-9.
7. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernández JA, Yang X, Riewald M, Weiler H, Ruggeri ZM and Griffin JH. Hyper-antithrombotic, Non-cytoprotective Glu149AlaActivated Protein C Mutant. Blood. 2009 Feb 24.
8. Mosnier LO, Yang X, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activatible fibrinolysis inhibitordependent cytoprotective functions J Biol Chem. 2007 Nov 9;282(45):33022-33
9. Kerschen EJ, Fernandez JA, Cooley BC, Yang X, Sood R, Mosnier LO, Castellino FJ, Mackman N, Coughlin SR, Griffin JH & Weiler H. Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C.. J Exp Med. 2007 Oct 1;204(10):2439-48
10. Yang X, Chang YJ, Lin SW, Walsh PN. Identification of residues Asn89, Ile90, and Val107 of the factor IXa second epidermal growth factor domain that are essential for the assembly of the factor X-activating complex on activated platelets. J Biol Chem, Nov 5, 279(45):46400-5, 2004
11. Yang X and Walsh PN. An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex. Biochem J, Aug 15;390(Pt 1):157-67, 2005
ABSTRACTS:
1. Yang X, Banerjee Y, Fernández JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, WhiteAdams TC, McCarty OJ, Griffin JH. Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). Blood, 2008, Volume 112, issue 11, abstract number #695.
2. Mosnier LO, Yang X, Griffin JH. Preservation of Beneficial TAFI Functions by an Activated Protein
C Variant With Normal Cytoprotective Functions but Minimal Anticoagulant Activity. Abstract #268 Blood, Volume 110, issue 11, November 16, 2007
3. Mosnier LO, Fernandez JA, Zampolli A, Yang X, Ruggeri ZM, Griffin JH. In vivo antithrombotic potency of engineered activated protein C variants. Abstract #2704, Blood, Volume 110, issue 11, November 16, 2007
4. Kerschen EJ, Fernandez JA, Yang X, Weiler H, Griffin JH and Mosnier LO. Translational research to improve therapy in severe sepsis using a genetically engineered activated protein C variant. Oct 2007
5. Mosnier LO, Yang X, Griffin JH, Dissection of structural requirements for activated protein C anticoagulant versus cytoprotective activities, J Thromb and Hemost, 2007, abstract number OW092
6. Yang X, Mosnier LO, Griffin JH, Activated protein C requires residues 176-178 for normal anticoagulant, anti-apoptotic and anti-inflammatory activities, J Thromb and Hemost, 2007, abstract number OT090
7. Yang X, Griffin JH, Mosnier LO. Anti-inflammatory and anti-apoptotic activities of activated protein C are independent of anticoagulant activity. Blood, 2006,Volume 108, issue 11
8. Yang X, Chang YJ, Lin SW, Walsh PN. Identification of residues ASN 89, Ile 90 and Val 107 of the Factor IXa EGF2 domain that are essential for the assembly of the Factor X activating complex on activated platelets. Blood, 2003, Volume 102, Number 11, Abstract number 1091
9. Yang X and Walsh PN, The omega-loop within the Gla domain (G4-Q11) and the EGF2 domain (C88-C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets. J Thromb and Hemost 2003; Volume 1, Supplement 1: Abstract number OC198
10. Yang X and Walsh PN. The omega-loop within the Gla domain and the EGF2 domain of Factor IXa are both necessary and sufficient for platelet binding and the assembly of the FX activating complex. Blood, 2003, Volume 102, Number 11, Abstract number 1083

PRESENTATIONS:
1. 12/2008 Fiftieth annual meeting of American Society of Hematology, San Francisco, CA (Oral presentation). “Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2).”
2. 07/2007 XXIst Congress of the international society of thrombosis and hemostasis, Geneva, Switzerland (Oral presentation) “Activated protein C requires residues 176- 178 for normal anticoagulant, anti-apoptotic and anti-inflammatory activities.”
3. 12/2006 Forty-eighth annual meeting of American Society of Hematology, Orlando, FL (Oral Presentation). “Anti-inflammatory and anti-apoptotic activities of activated protein C are independent of anticoagulant activity.”
4. 12/2003 Forty-fifth annual meeting of American Society of Hematology, San Diego, CA (Poster Presentation #2) “Identification of residues ASN 89, Ile 90 and Val 107 of Xia Yang, Ph.D. Page 4 the Factor IXa EGF2 domain that are essential for the assembly of the Factor X activating complex on activated platelets.”
5. 07/2003 XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK
(Oral Presentation). “The omega-loop within the Gla domain (G4- Q11) and the EGF2 domain (C88C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets.”
6. 12/2003 Forty-fifth annual meeting of American Society of Hematology, San Diego, CA (Poster Presentation#1) “The omega-loop within the Gla domain and the EGF2 domain of Factor IXa are both necessary and sufficient for platelet binding and the assembly of the FX activating complex.” ·

Build Your Own Now

DISCLAIMER

Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.

Resume Overview

Companies Worked For:

  • Metacrine Inc.
  • Regulus Therapeutics
  • Johnson And Johnson, Immunology Department
  • The Scripps Research Institute

School Attended

  • Temple University
  • Wuhan University

Job Titles Held:

  • Senior Scientist
  • Scientist-Senior Scientist
  • Postdoctoral Fellow
  • Postdoctoral Research Associate

Degrees

  • Ph.D.
    Bachelor of Science

Create a job alert for [job role title] at [location].

×

Advertisement

Similar Resumes

View All
Senior-Scientist-resume-sample

Senior Scientist

GlaxoSmithKline Pharmaceuticals

Darby, Pennsylvania

Senior-Scientist-resume-sample

Senior Scientist

Arcus Biosciences

Fremont, California

Senior-Scientist-resume-sample

Senior Scientist

GlaxoSmithKline

Wilmington, Delaware

About
  • About Us
  • Privacy Policy
  • Terms of Use
  • Sitemap
Help & Support
  • Work Here
  • Contact Us
  • FAQs
Languages
  • EN
  • UK
  • ES
  • FR
  • IT
  • DE
  • NL
  • PT
  • PL
Customer Service
customerservice@livecareer.com
800-652-8430 Mon- Fri 8am - 8pm CST
Sat 8am - 5pm CST, Sun 10am - 6pm CST
  • Stay in touch with us
Site jabber winner award

© 2021, Bold Limited. All rights reserved.